AbbVie Announces U.S. FDA Granted Breakthrough Therapy Designation (BTD) to Telisotuzumab Vedotin (Teliso-V) for Previously Treated Non-Small Cell Lung Cancer
KPLC 7 News,
- Teliso-V, an investigational antibody-drug conjugate (ADC), is being studied in patients with previously treated non-small…